Physician

Devapiran Jaishankar, M.D.

According to 2025 Medicare claims, Devapiran Jaishankar, M.D. (NPI: 1225038490) practices medical oncology in the Kingsport-Bristol, TN-VA market, with the plurality of this provider's patient population coming from Sullivan, TN. This provider's primary affiliated billing organization is TENNESSEE CANCER SPECIALISTS PLLC (NPI: 1841228871; TIN: 200677400) and primary practice location at 37660-7435. Jaishankar is affiliated with the AnewCare Collaborative, LLC (ACO ID: A1241), participating under the MSSP model.

Jaishankar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 298 traditional Medicare patients, billed 14,815 HCPCS/CPT codes, and received $442,673 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,010 prescription claims across 248 beneficiaries totaling $2,371,629 in drug costs, led by Imbruvica (Ibrutinib). 2023 DME data shows 23 claims. Open Payments data shows 38 records totaling $851. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $68,556 and ending at $442,673. Concurrently, Part D prescription costs have risen steadily, from $1,409,774 to $2,371,629. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	374	1,006	$68,556
2016	383	883	$68,044
2017	338	879	$79,179
2018	292	783	$64,909
2019	321	790	$57,971
2020	316	785	$64,822
2021	371	1,328	$163,025
2022	344	905	$98,494
2023	334	735	$67,659
2024	298	14,815	$442,673

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	212	1,614	$1,409,774
2016	178	1,247	$989,781
2017	164	991	$1,312,191
2018	166	942	$1,999,482
2019	160	962	$1,456,914
2020	169	1,003	$1,610,711
2021	251	1,530	$3,191,193
2022	255	1,424	$2,418,839
2023	235	1,206	$2,095,547
2024	248	1,010	$2,371,629

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	69	$5,103
2016	N/R	62	$12,133
2017	N/R	36	$688
2018	N/R	15	$5,389
2019	N/R	66	$5,883
2020	N/R	35	$2,350
2021	N/R	37	$2,937
2022	N/R	76	$2,599
2023	N/R	23	$3,414
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	94	193	$114
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	132	142	$74
80053	Blood test, comprehensive group of blood chemicals	73	151	$10
36415	Insertion of needle into vein for collection of blood sample	85	217	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	83	203	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	30	840	$457,984
Revlimid	Lenalidomide	22	609	$365,775
Tukysa	Tucatinib	11	330	$245,604
Ibrance	Palbociclib	12	322	$186,206
Abiraterone Acetate	Abiraterone Acetate	17	510	$27,981

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	38	$851	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Devapiran Jaishankar, M.D.?

Tedicare shows public-source Medicare data for Devapiran Jaishankar, M.D. (NPI 1225038490), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Devapiran Jaishankar, M.D. have ACO affiliation data?

Devapiran Jaishankar, M.D. is shown with ACO affiliation data for AnewCare Collaborative, LLC (MSSP, ACO ID A1241).

What billing organization is linked to Devapiran Jaishankar, M.D.?

Devapiran Jaishankar, M.D. is linked to TENNESSEE CANCER SPECIALISTS PLLC (billing NPI 1841228871) in the available physician profile data.

Does Devapiran Jaishankar, M.D. have Open Payments data?

Devapiran Jaishankar, M.D. has 38 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.